Alec Stranahan
BofA Securities, Research Division

Hello, everyone. My name is Alec Stranahan. I cover CRISPR Therapeutics at Bank of America. Thanks for joining this session with CRISPR. And pleased to introduce Sam Kulkarni, the Chief Executive Officer at CRISPR for this 30-minute fireside. Thanks for being here, Sam.

Samarth Kulkarni
CEO & Chairman

Thanks for having us.

Alec Stranahan
BofA Securities, Research Division

Yes. Great. Well, maybe just to kick off, you've described 2026 as kind of a stepping stone year, some pretty important early readouts from 6 programs in the second half. I guess how do you sort of prioritize the focus within the company on the earlier stage versus supporting CASGEVY? And where are you sort of directing investors sort of in the remainder of this year?

Samarth Kulkarni
CEO & Chairman

Yes. It's an exciting time for the company. We've been around as a company for about 11 years. The first phase of the company was all about CASGEVY and bringing that to the market to patients that really needed a drug, that were suffering from sickle cell and thalassemia. And upon the completion of that phase or as we got that to the end of the clinical trials and into commercialization, we started a number of other programs.

And at this point, we're in the second phase of the company where these assets are starting to mature, and we're seeing more data. So we have 6 assets, as you said, that will all have data in the next 12 to 18 months. And those are one bucket of that is in cardiovascular. That's with